Navigation Links
AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedy's Disease)
Date:1/25/2011

SAN DIEGO, Jan. 25, 2011 /PRNewswire/ -- AndroScience Corp. (ASC), based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).  Through a joint research effort with the Neurogenetics Branch of the NINDS, ASC will use the funding to pursue development of an oral drug treatment for spinal and bulbar muscular atrophy (SBMA) or Kennedy's Disease, a rare hereditary neurodegenerative disease, which currently has no approved drug available to patients.  Key pathological features of SBMA include progressive motor neuropathy and androgen insensitivity syndrome caused by a distinctive mutation within the androgen receptor (AR) gene.  ASC has developed a unique platform of therapeutic small molecule drugs, which selectively and potently enhance degradation of the AR protein, termed AR degradation enhancers (ARD enhancers).

"Given encouraging pre-clinical results and the clear need for a new therapeutic option for SBMA patients, ASC is excited to continue advancing preclinical development of this promising novel drug candidate," said ASC President Charles Shih, Ph.D. "The funding provided by the NINDS/NIH will significantly propel our efforts in validating ARD enhancers as a disease-modifying therapeutic intervention against such a rare and devastating neurodegenerative illness."

This $3.8 Million cooperative translational research grant will leverage expertise from the NINDS and draw upon ASC's innovative approach to targeting the mutant androgen receptor (AR).  The goals of the grant will be to first validate an orally administered ARD enhancer drug is efficacious in the SBMA transgenic animal model, and further, to complete preclinical toxicology, safety pharmacology, and ADME studies necessary in supporting of an IND filing to commence human clinical studies.  To date, ASC has provided robust proof of concept data using an ARD enhancer compound; demonstrating treatment ameliorates cardinal features of SBMA neuromuscular pathology, restores functional activity, and improves survival in a SBMA transgenic mouse model.

About Spinal Bulbar Muscular Atrophy (SBMA) – Kennedy's DiseaseSpinal and bulbar muscular atrophy (SBMA or Kennedy's Disease) is a rare hereditary neurodegenerative disease that affects lower motor neurons, with progressive muscle atrophy and weakness of the bulbar, facial, and limb muscles. The disease results in progressive dysphasia, motor dysfunction, and typically affects men in the fourth or fifth decade of life.  SBMA is caused by a mutation in the X-chromosome linked androgen receptor (AR) gene that results in excessive repeats of the amino acid glutamine (polyQ) within AR protein.  A molecular genetic test is clinically available which has a 100% mutation detection rate to definitively diagnose SBMA.  Neurotoxicity caused by these expanded polyQ AR aggregates is believed to play a pivotal role in the pathogenesis of SBMA.  SBMA is considered an orphan drug indication and no approved therapy exists.  Furthermore, very few drug candidates are being evaluated in clinical trials.  

About AndroScience CorporationAndroScience (ASC) is a privately held San Diego, California based pharmaceutical company applying expertise in natural product chemistry to develop proprietary small molecule drug compounds targeting disease dependent intracellular signaling events related to the Androgen Receptor (AR) and selective Signal Transducer and Activation of Transcription (STAT) pathways.  The company is focused on therapeutic indications of significant medical and commercial importance, including androgen-dependent diseases in both topical and systemic treatment settings and novel approaches to the treatment of cancer.  Active ARD enhancer therapeutic programs include topical indications: acne (in Phase 2b clinical trail), alopecia (male pattern baldness) and wound healing;  and systemic indications: SBMA, prostate cancer, HBV-induced HCC, and bladder cancer. Currently, the newly discovered STAT inhibitor compounds demonstrate potent anti-tumor properties across a wide range of solid and hematological tumors.  ASC is actively seeking licensing partners for multiple products at various stages of program development with both domestic and international based pharmaceutical companies.

www.androscience.com

About National Institute of Neurological Disorders and Stroke (NINDS), NIHThe Intramural Research Program of the National Institute of Neurological Disorders and Stroke (NINDS) is one of the largest neuroscience research centers in the world. Investigators in the NINDS intramural program conduct research in the basic, translational, and clinical neurosciences. Their specific interests cover a broad range of neuroscience research including molecular biophysics, synapses and circuits, neuronal development, integrative neuroscience, brain imaging and neurological disorders. Through collaboration, pre- and postdoctoral training programs, jointly sponsored seminar series and special interest groups, NINDS investigators and investigators in other intramural programs (NIMH, NEI, NIDCD and NICHD) contribute to a vital and growing neuroscience research community at the National Institutes of Health.

www.ninds.nih.govFor more information, contact AndroScience CorporationAddress: AndroScience™ Corporation11175 Flintkote Ave., Ste. FSan Diego, CA 92121Phone: (858) 638-7230General Inquiries: info88@androscience.comBusiness Development Inquiries: bnewcomer@androscience.com
'/>"/>

SOURCE AndroScience Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AndroScience Corporation Forms Strategic Alliance With Taiwan Based Orient Europharma to Develop Novel Topical Acne Therapeutic
2. AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
3. Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
4. Celsion Corporation Announces Completion of $5.1 Million Registered Direct Offering
5. CVS Caremark Corporation to Hold Fourth Quarter 2010 Conference Call
6. Medical Simulation Corporation to Feature Full Spectrum of Services and Simulation-Based Curriculum at the 11th Annual International Meeting on Simulation in Healthcare
7. Stryker Corporation Named One of FORTUNE Magazines 100 Best Companies to Work For
8. Luminex Corporation Fourth Quarter and Full Year 2010 Earnings Release Scheduled for February 7, 2011
9. Kensey Nash Corporation Announces Its Second Quarter Fiscal Year 2011 Earnings Release Date and Teleconference
10. Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V.
11. TREVENTIS Corporation Founder Wins Prestigious Discovery Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
Breaking Medicine News(10 mins):